Venture Life Group PLC (LON:VLG)‘s stock had its “buy” rating restated by research analysts at Panmure Gordon in a report issued on Wednesday. They presently have a GBX 128 ($1.67) price objective on the stock. Panmure Gordon’s target price suggests a potential upside of 134.86% from the stock’s previous close.

Separately, Beaufort Securities reiterated a “speculative buy” rating on shares of Venture Life Group PLC in a report on Monday, August 1st.

Shares of Venture Life Group PLC (LON:VLG) opened at 54.50 on Wednesday. Venture Life Group PLC has a one year low of GBX 43.00 and a one year high of GBX 81.92. The company has a 50 day moving average price of GBX 51.62 and a 200-day moving average price of GBX 56.43. The stock’s market cap is GBX 18.75 million.

About Venture Life Group PLC

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The Company focuses on developing, manufacturing and commercializing products for the ageing population. Its product range includes medical devices (such as those for minor aches and pains, and alleviating symptoms associated with hemorrhoids and itchy skin), food supplements (such as those for lowering cholesterol and improving brain function), and dermo-cosmetics and cosmetics for addressing the signs of skin-ageing.

Receive News & Ratings for Venture Life Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venture Life Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.